[go: up one dir, main page]

SG11201606869TA - Antimitotic amides for the treatment of cancer and proliferative disorders - Google Patents

Antimitotic amides for the treatment of cancer and proliferative disorders

Info

Publication number
SG11201606869TA
SG11201606869TA SG11201606869TA SG11201606869TA SG11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA SG 11201606869T A SG11201606869T A SG 11201606869TA
Authority
SG
Singapore
Prior art keywords
antimitotic
amides
cancer
treatment
proliferative disorders
Prior art date
Application number
SG11201606869TA
Inventor
Adam Siddiqui-Jain
Original Assignee
Frost Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frost Biolog Inc filed Critical Frost Biolog Inc
Publication of SG11201606869TA publication Critical patent/SG11201606869TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201606869TA 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders SG11201606869TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21
PCT/US2015/016928 WO2015127284A2 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Publications (1)

Publication Number Publication Date
SG11201606869TA true SG11201606869TA (en) 2016-09-29

Family

ID=52684675

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606869TA SG11201606869TA (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders
SG10202000590SA SG10202000590SA (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202000590SA SG10202000590SA (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Country Status (15)

Country Link
US (4) US10016398B2 (en)
EP (1) EP3107909B1 (en)
JP (1) JP6506313B2 (en)
KR (1) KR102420508B1 (en)
CN (2) CN114634483B (en)
AU (1) AU2015218775C1 (en)
BR (1) BR112016019161B1 (en)
CA (1) CA2940237C (en)
ES (1) ES2893374T3 (en)
IL (1) IL247293B (en)
MX (1) MX390530B (en)
RU (1) RU2713179C2 (en)
SG (2) SG11201606869TA (en)
WO (1) WO2015127284A2 (en)
ZA (1) ZA201606471B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
CA2940237C (en) 2014-02-21 2023-03-07 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
CN106727583A (en) * 2016-12-12 2017-05-31 范旭升 A kind of pharmaceutical composition for treating diastolic heart failure
WO2019014460A1 (en) * 2017-07-12 2019-01-17 The Brigham And Women's Hospital, Inc. Eaat2 enhancing molecules
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
KR20250173438A (en) * 2024-05-30 2025-12-10 삼진제약주식회사 NR2F6 inhibitor and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
MXPA02012045A (en) * 2000-06-05 2003-10-15 Dong A Pharm Co Ltd Novel oxazolidinone derivatives and a process for the preparation thereof.
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
KR20070030244A (en) * 2004-06-30 2007-03-15 노파르티스 아게 How to Increase the Susceptibility of Peptide Deformillase Inhibitors Using Effluent Pump Inhibitors
JPWO2007018319A1 (en) * 2005-08-11 2009-02-19 武田薬品工業株式会社 Pyridylphenol compounds and uses thereof
US20070254926A1 (en) * 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
JP2010510191A (en) 2006-11-17 2010-04-02 スミスクライン ビーチャム コーポレーション 2-Carboxythiophene derivatives as antiviral agents
WO2008125839A2 (en) * 2007-04-12 2008-10-23 Piramed Limited Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
CA2739321A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
SI2475368T1 (en) * 2009-09-11 2015-03-31 Amgen Inc. N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
PT2563776T (en) * 2010-04-27 2016-09-19 Calcimedica Inc Compounds that modulate intracellular calcium
US20130063385A1 (en) * 2010-05-14 2013-03-14 Sharp Kabushiki Kaisha Portable information terminal and method for controlling same
TWI541243B (en) * 2010-09-10 2016-07-11 拜耳知識產權公司 Substituted imidazopyridazines
WO2012100135A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Picolinamide inhibitors of kinases
BR112013020270A2 (en) * 2011-02-10 2016-07-12 Syngenta Participations Ag pyrazole derivatives microbicides
JP5985611B2 (en) * 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション Compounds for inflammation and immune related applications
CA2853485A1 (en) * 2011-10-28 2013-05-02 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CA2940237C (en) * 2014-02-21 2023-03-07 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders

Also Published As

Publication number Publication date
KR102420508B1 (en) 2022-07-13
CN114634483B (en) 2024-08-13
ZA201606471B (en) 2025-06-25
US20170172984A1 (en) 2017-06-22
US12383533B2 (en) 2025-08-12
RU2713179C2 (en) 2020-02-04
US20180325871A1 (en) 2018-11-15
MX390530B (en) 2025-03-20
ES2893374T3 (en) 2022-02-08
CN114634483A (en) 2022-06-17
AU2015218775C1 (en) 2020-01-16
WO2015127284A3 (en) 2015-10-15
BR112016019161A2 (en) 2017-08-15
MX2016010877A (en) 2017-05-04
IL247293B (en) 2021-01-31
BR112016019161B1 (en) 2022-12-20
US10016398B2 (en) 2018-07-10
JP2017506267A (en) 2017-03-02
IL247293A0 (en) 2016-09-29
RU2016135555A (en) 2018-03-28
US20220008395A1 (en) 2022-01-13
CA2940237C (en) 2023-03-07
WO2015127284A2 (en) 2015-08-27
EP3107909A2 (en) 2016-12-28
SG10202000590SA (en) 2020-03-30
AU2015218775A1 (en) 2016-08-25
US20200397758A1 (en) 2020-12-24
US10772872B2 (en) 2020-09-15
RU2016135555A3 (en) 2018-10-05
JP6506313B2 (en) 2019-04-24
EP3107909B1 (en) 2021-07-14
CA2940237A1 (en) 2015-08-27
AU2015218775B2 (en) 2019-06-20
US11129813B2 (en) 2021-09-28
CN106068263A (en) 2016-11-02
KR20160116009A (en) 2016-10-06

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL262416A (en) Materials and methods for treatment of hemoglobinopathies
IL248455B (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
SG11201706766WA (en) Materials and methods for treatment of hemoglobinopathies
GB201405232D0 (en) Apparatus and methods for the treatment of ocular disorders
SG11201703193XA (en) Treatment for depression and depressive disorders
PL3122358T3 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
EP3157336A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
GB201506851D0 (en) Apparatus and method for providing hyperthermia therapy
IL251904B (en) Apilimod for use in the treatment of melanoma
IL247293A0 (en) Antimitotic amides for the treatment of cancer and proliferative disorders
EP3154616A4 (en) Methods and apparatus for treatment of respiratory disorders
HUE069644T2 (en) Method and apparatus for the manufacture of parts
AP2017009724A0 (en) Methods and compositions for treating hiv-related disorders
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
HK1232858A1 (en) Antimitotic amides for the treatment of cancer and proliferative disorders
AU2016905121A0 (en) Methods of Treating Proliferative Disorders
PL3190212T3 (en) Apparatus for the surface treatment of a continuous material and its use
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201414904D0 (en) Materials and methods for treating cancer
HK1234988A1 (en) Combinations of fomoterol and budesunide for the treatment of copd
GB201420040D0 (en) Apparatus and method of using the same